A Systematic Review of the Incidence and Prevalence of Long-Term Neurological Conditions in the UK
Progressive neurological diseases vary in presentation, both in timescale and severity. This review forms part of a Policy Research Programme commissioned by the National Institute for Health Research to assess disease burden on service user, family and health and social care services. The investigated conditions were requested by
Rationale and Aim of Review
The aim was to systematically identify and update the incidence and prevalence of the following long-term neurological conditions:
• Motor neurone disease • Huntington's disease • Progressive supranuclear palsy • Multiple system atrophy • Postpolio syndrome • Charcot-Marie-Tooth disease • Dominantly inherited ataxias Knowledge of these data is valuable in informing future research and health service policies.
Methods
The review protocol is accessible at http://www.ltnc.org.uk/ research_files/RESULT_study.html. Population-based studies of incidence and prevalence were sought.
Scoping Search
A scoping search identified existing reviews of incidence and prevalence. Existing reviews would be updated, not repeated. 
Main Search Strategy
The search strategy (Appendix 1) identified articles from Medline, Embase and CINAHL. The Cochrane Library (CENTRAL) and databases of ongoing research and unpublished literature were also searched. Reference lists of included articles were assessed to capture further articles omitted from the search strategy.
Inclusion/Exclusion Criteria
Articles were included based on the criteria outlined in table 1 . Comprehensive case ascertainment was required in order to ensure maximum patient capture. Studies before 1988 were excluded as the review aimed to present up-to-date statistics. Strict diagnostic criteria were set to minimise bias from misdiagnoses. Inclusion was based on agreement between 2 of the independent reviewers (T.H., J.C., G.J., J.R.). In cases of non-consensus, a third independent review was obtained. In cases of incomprehensive study methodology, authors were approached to determine a study's potential inclusion.
Data Extraction
The following data were extracted into tables:
• Source: authors and journal published • Study design: e.g. cross-sectional, cohort, etc.
• Population denominator 
Data Analyses
Incidences were reported as ranges. Pooling statistics was not possible due to methodological heterogeneity and shared population denominations between certain studies.
Results

Existing Systematic Reviews
No existing systematic reviews of incidence and prevalence were identified.
Study Yield
The initial search yielded 8,869 references; 311 were identified as potentially relevant. Of these, 9 met the inclusion criteria and were included in the review ( fig. 1 ) .
Included Studies by Condition
Motor Neurone Disease (Amyotrophic Lateral Sclerosis) Five studies assessed the incidence/prevalence of motor neurone disease ( table 2 ) . Total population coverage was 11,498,075, although some overlap between studies emerged. The incidence of motor neurone disease in the UK ranged from 1.06 to 2.4/100,000 person-years (in- Huntington's Disease Three studies assessed the prevalence of Huntington's disease ( table 3 ) . No reports of incidence were identified. Total population coverage was 5,483,871. The prevalence ranged from 4.0 to 6.4/100,000 of the populations studied.
Progressive Supranuclear Palsy One study assessed the prevalence of progressive supranuclear palsy ( table 4 ). The study included 3 substudies. A national study of the entire UK population, a regional study covering a catchment of 2,598,240 and a community study covering a catchment of 259,998 people. The prevalence ranged from 1.0/100,000 in the national study to 6.5/100,000 in the community study. However, only the community study had a comprehensive case ascertainment and we therefore report these statistics in our results. Table 5 illustrates a summary of results identified in the study.
Results Summary
Excluded Studies
Four studies illustrated in table 6 were excluded from the review.
Articles yielded from initial search strategy: n = 8,869
Articles retained for further review: n = 311
Articles retained for further review: n = 30
Articles retained for further review: n = 13
Articles included in review: n = 9 motor neurone disease: n = 5 Huntington's disease: n = 3 Charcot-Marie-Tooth disease: n = 0 progressive supranuclear palsy: n = 1 multiple system atrophy: n = 0 postpolio syndrome: n = 0 dominantly inherited ataxias: n = 0
Excluded -not studies of long-term neurological conditions of interest: n = 8,558
Excluded -not incidence/prevalence studies of conditions of interest: n = 281
Excluded -study published before 1988: n = 17
Excluded -inclusion criteria not fulfilled: n = 4 
Unreported Conditions
No articles relating to postpolio syndrome, CharcotMarie-Tooth disease, multiple system atrophy and dominantly inherited ataxias in the UK were identified that met the inclusion criteria. However, some studies were identified that did not meet the required criteria. Whilst it would be inappropriate to include these studies in the results, table 7 provides incidence and prevalence statistics for excluded studies in conditions not represented in the results to provide at least some information on these conditions. However, one must view these results with caution due to the associated methodological limitations.
Discussion
The review aimed to systematically report the incidence and prevalence of long-term neurological conditions in the UK. Review findings and the variation between studies are discussed.
Motor Neurone Disease
Some variation in incidence is evident. An incidence of 1.06/100,000 person-years was found in South East England [1] , compared to 2.4 in Scotland [2] . Differences in age structure between geographical locations may influence variations in incidence and prevalence rates. The literature suggests that onset generally occurs after 40 years age, with a peak incidence between 55 and 75 years [14, 15] . Data from the 2001 census [16, 17] indicate that 32% of the population of Greater London are over 45 years of age compared to 40% of the Scottish population. Furthermore, approximately 10% of the Greater London population are in the 60-to 75-year age bracket compared to 14% in Scotland. Such statistics are likely to make small differences in incidence and prevalence rates but would not account for any large differences. Other than these geographical considerations, there is no evidence of environmental factors to explain differences. Familial cases are reported as less than 10%, making it unlikely that geographical clustering of families with motor neurone disease affected observed figures. Methodological differences within the study design may explain observed differences. Omissions of small numbers of unidentified cases could influence rates reported substantially. However, case ascertainment and diagnostic methods appear similar, and differences could be attributable to chance.
The prevalence was consistent across studies, ranging from 4.02 to 4.91/100,000. These figures sit at the lower end of the reported global prevalence (4-10/100,000) [18] [19] [20] [21] [22] . However, it is worth noting that the actual prevalence may be higher as those without a diagnosis are not included in these estimates.
Huntington's Disease
The prevalence ranged from 4.0 to 6.4/100,000. This is contrary to reported global rates (0.4-0.5/100,000), but comparable to the prevalence reported in other Western countries (8-10/100,000) [23] .
Differences in prevalence between studies could be attributable to geographical variation due to the hereditary nature of the disease. A previous study reported a prevalence of 9.94/100,000 in the Grampian region of Scotland in 1987 [13] , compared to 4.0/100,000 in Oxfordshire in 1993 [8] . Authors report the Grampian region to have low migration levels due to thriving local communities, compared to relatively high migration in the Oxfordshire region. A closed gene pool population compared to a population with high migration rates may explain such discrepancies.
The possibility of methodological differences between studies remains and could be a factor in reported discrepancies. Case ascertainment appears consistent between the studies. However, some studies used a genetic test as a diagnostic confirmation [6] , whereas others appeared to assess records and registers for diagnostic confirmation [7] . Consequently, in studies using genetic testing, positive diagnoses were made for presymptomatic patients, which was not possible in studies where only symptomatic patients were included. As mentioned previously, in rare conditions incomplete case ascertainment or disease misclassification can skew the reported incidence/prevalence significantly in both directions. Progressive Supranuclear Palsy Evidence suggests progressive supranuclear palsy is sporadic. Tau gene mutations have been identified as a predisposition. However, two thirds of the global population possess this polymorphism. Consequently, other factors may be more important in progressive supranuclear palsy.
The prevalence ranged from 1.0/100,000 in the national study by Nath et al. [9] to 6.5/100,000 in the community study by the same authors. However, the authors ad- [12] Multiple system atrophy/progressive supranuclear palsy
Incomprehensive case ascertainment: 33/202 patients (16%) identified as potential progressive supranuclear palsy/multiple system atrophy patients declined to be assessed further, therefore complete case ascertainment was not possible; estimates of incidence/prevalence are likely to be too low Simpson and Johnston (1989) [13] Huntington's disease Although study published after 1988, data refer to pre-1988 incidence and prevalence mit the case ascertainment was not 'active' and fully comprehensive due to the denominator size and report that 81% of the cases may be unascertained based on the community study prevalence. The regional study fits within the reported global prevalence range (1.39-5.8/100,000) [24] [25] [26] . As the condition is sporadic, the greater prevalence observed in the community study is probably due to a more complete case ascertainment.
General Points
A fundamental point is that the incidence and prevalence reported should be regarded as minimum figures. Assuming studies had 100% case ascertainment of diagnosed patients, the statistics would still omit undiagnosed patients. Consequently, such studies will underpredict incidence and prevalence. One could argue that due to the lack of firm diagnostic criteria, diagnoses may switch between conditions, resulting in under-and overestimation of figures. However, misclassifications and changes in diagnoses would have insignificant bearing on statistics in comparison to the magnitude of effect of an exclusion of undiagnosed patients.
Non-Reported Conditions
No studies of the incidence/prevalence of CharcotMarie-Tooth disease or postpolio syndrome were identified. In Charcot-Marie-Tooth disease, this was surprising as it is reported as the most prevalent condition in global studies [27] . Furthermore, one may expect more extensive research with follow-up in a non-life-limiting condition. With regard to postpolio syndrome, despite a number of intervention trials [28] [29] [30] [31] [32] [33] , the lack of reported incidence/prevalence may reflect difficulties in confirming diagnoses due to the symptoms being similar to those associated with natural ageing. Accurate case ascertainment would be difficult and expose statistics to bias.
Conclusion
In conclusion, the review reported incidence/prevalence ranges for the long-term neurological conditions from all identified studies in the UK since 1988. The rates varied between studies, particularly for Huntington's disease, possibly attributable to geographical variation. The exclusion of articles due to methodological limitations suggests future epidemiological studies require comprehensive case ascertainment and strict and standardised diagnostic methods. Such safeguards will ensure more comprehensive reviews of incidence and prevalence, covering a wider denominator population of the UK.
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